Frisbie to Lead C. Wayne McIlwraith Translational Medicine Institute
David Frisbie, DVM, PhD, DACVS, and a Diplomate of the American College of Veterinary Sports Medicine and Rehabilitation, is a professor in the Department of Clinical Sciences and an equine surgeon. Frisbie has been named director of the C. Wayne McIlwraith Translational Medicine Institute. He has been a faculty member in the College of Veterinary Medicine and Biomedical Sciences at Colorado State University for nearly 20 years and is an internationally recognized expert in orthopedic surgery, research and sports medicine.
Frisbie is a respected leader within the college and nationally, and he has held numerous board and leadership positions throughout his career. He currently serves as the vice president of the American Association of Equine Practitioners‘ board of directors, and will become the board’s president in 2020. Nearly 9,300 veterinarians and veterinary students in 61 countries are members of the association.
He has played an integral role in creating the vision and mission of the Translational Medicine Institute, and has taken the lead on overseeing construction of the institute and day-to-day operations.
“I can think of no one better suited to lead the next steps for the Translational Medicine Institute,” said Dr. Mark Stetter, dean of the College of Veterinary Medicine and Biomedical Sciences.
Frisbie is the director of research for the Orthopaedic Research Center, a position he will continue to hold, and has served as interim director of operations for the Translational Medicine Institute since 2016.
In addition to continuing his research, Frisbie has remained active in teaching, advising and mentoring graduate students and junior faculty in the Orthopaedic Research Center and has led the Translational Medicine Institute’s Steering Committee in strategic planning, working with CSU’s partners.
“Dave has been a tireless leader, and he has demonstrated a strong commitment to making CSU the best it can be,” said Stetter. “He has played a pivotal role in the actualization of the Translational Medicine Institute as a premier research facility,” he added.
Construction of the Translational Medicine Institute building will be complete by the end of November, with a ceremonial grand opening scheduled for May 6, 2019. In the months to come, Frisbie will continue to refine programmatic aspects of the institute, finalizing policies and procedures. He and his team will also work to fill new positions associated with the institute’s strategic goals.